Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New chemo strategy aims to boost pancreatic cancer survival

NCT ID NCT02959879

Summary

This study tested whether giving chemotherapy before surgery (neoadjuvant chemo) works better than the standard approach of surgery followed by chemo for pancreatic cancer that can be surgically removed. It compared two different chemotherapy combinations (FOLFOX and FOLFIRINOX) given before surgery to the standard treatment. The goal was to see if this approach helps more patients survive longer and reduces the chance of the cancer coming back.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE PANCREATIC DUCT ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Rouen University Hospital

    Rouen, France

Conditions

Explore the condition pages connected to this study.